EP3896062A4 - Isoindolinverbindung, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und verwendung der isoindolinverbindung - Google Patents
Isoindolinverbindung, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und verwendung der isoindolinverbindung Download PDFInfo
- Publication number
- EP3896062A4 EP3896062A4 EP19893951.4A EP19893951A EP3896062A4 EP 3896062 A4 EP3896062 A4 EP 3896062A4 EP 19893951 A EP19893951 A EP 19893951A EP 3896062 A4 EP3896062 A4 EP 3896062A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- isoindoline compound
- preparation
- application
- pharmaceutical composition
- isoindoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Isoindoline compound Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811488140 | 2018-12-06 | ||
PCT/CN2019/123643 WO2020114482A1 (zh) | 2018-12-06 | 2019-12-06 | 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3896062A1 EP3896062A1 (de) | 2021-10-20 |
EP3896062A4 true EP3896062A4 (de) | 2022-06-15 |
Family
ID=70973433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19893951.4A Pending EP3896062A4 (de) | 2018-12-06 | 2019-12-06 | Isoindolinverbindung, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und verwendung der isoindolinverbindung |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220041578A1 (de) |
EP (1) | EP3896062A4 (de) |
CN (1) | CN111285850B (de) |
AU (1) | AU2019392231B2 (de) |
CA (1) | CA3122317C (de) |
WO (1) | WO2020114482A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102672549B1 (ko) * | 2018-09-30 | 2024-06-10 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 이소인돌린계 화합물, 이의 제조 방법, 약학 조성물 및 용도 |
WO2021083328A1 (zh) * | 2019-10-30 | 2021-05-06 | 中国科学院上海药物研究所 | 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途 |
AU2021262334B2 (en) * | 2020-04-30 | 2023-12-14 | Shanghaitech University | Heterocycle and glutarimide skeleton-based compounds and applications thereof |
CN114456173B (zh) * | 2020-11-10 | 2023-09-19 | 江苏恒瑞医药股份有限公司 | 稠环基取代的环己二酰亚胺类衍生物、其制备方法及其在医药上的应用 |
TW202241872A (zh) * | 2021-01-05 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠雜環基取代的環己二醯亞胺衍生物、其製備方法及其在醫藥上的應用 |
CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
CN114805357B (zh) * | 2021-01-21 | 2023-12-19 | 四川大学 | 一种靶向setdb1-ttd的小分子抑制剂及其制药用途 |
CN115246783B (zh) * | 2021-04-26 | 2024-06-21 | 中国科学院上海药物研究所 | 1,3-环己二酮类化合物及其药物组合物和应用 |
CN117186061A (zh) * | 2022-06-07 | 2023-12-08 | 天津谷堆生物医药科技有限公司 | 4-羰基氨基异吲哚啉-1-酮衍生物、包括其的组合物及使用方法 |
CN117186062A (zh) * | 2022-06-07 | 2023-12-08 | 天津谷堆生物医药科技有限公司 | 4-羰基氨基异吲哚啉-1,3-二酮类化合物及其制备方法、药物组合及用途 |
WO2023246944A1 (zh) * | 2022-06-24 | 2023-12-28 | 中国科学院上海药物研究所 | 一类取代的4-氨基异吲哚啉类化合物、其制备方法、药物组合物及应用 |
CN118019736A (zh) * | 2022-09-08 | 2024-05-10 | 标新生物医药科技(上海)有限公司 | 基于cereblon蛋白设计的分子胶化合物及其应用 |
US20240158370A1 (en) * | 2022-09-09 | 2024-05-16 | Innovo Therapeutics, Inc. | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS |
WO2024109918A1 (zh) * | 2022-11-24 | 2024-05-30 | 西藏海思科制药有限公司 | 一种gspt1降解剂及其在医药上的应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
KR20080042158A (ko) | 2005-08-31 | 2008-05-14 | 셀진 코포레이션 | 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법 |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
BRPI0716092A2 (pt) | 2006-08-30 | 2013-09-17 | Celgene Corp | composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples. |
EP2142534B1 (de) | 2007-03-20 | 2016-08-10 | Celgene Corporation | 4'-o-substituierte isoindolin derivate, diese enthaltende zusammensetzungen und anwendungsverfahren dafür |
EP2985281B1 (de) | 2008-10-29 | 2017-12-27 | Celgene Corporation | Isoindolin-verbindungen zur behandlung von krebs |
US9045453B2 (en) | 2008-11-14 | 2015-06-02 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
ES2730763T3 (es) * | 2010-02-11 | 2019-11-12 | Celgene Corp | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos |
JP6546997B2 (ja) | 2014-10-30 | 2019-07-17 | カンプー バイオファーマシューティカルズ リミテッド | イソインドリン誘導体、その中間体、製造方法、薬物組成物及び応用 |
EP3440082A1 (de) * | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunktionelle zwischenprodukte für den ligandenabhängigen zielproteinabbau |
WO2017197051A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
WO2017223452A1 (en) * | 2016-06-23 | 2017-12-28 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use |
US10723717B2 (en) * | 2016-12-23 | 2020-07-28 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
JP2021519337A (ja) * | 2018-03-26 | 2021-08-10 | シー4 セラピューティクス, インコーポレイテッド | Ikarosの分解のためのセレブロン結合剤 |
-
2019
- 2019-12-06 CA CA3122317A patent/CA3122317C/en active Active
- 2019-12-06 US US17/311,580 patent/US20220041578A1/en active Pending
- 2019-12-06 EP EP19893951.4A patent/EP3896062A4/de active Pending
- 2019-12-06 WO PCT/CN2019/123643 patent/WO2020114482A1/zh unknown
- 2019-12-06 AU AU2019392231A patent/AU2019392231B2/en active Active
- 2019-12-06 CN CN201911240570.7A patent/CN111285850B/zh active Active
Non-Patent Citations (1)
Title |
---|
No further relevant documents disclosed * |
Also Published As
Publication number | Publication date |
---|---|
WO2020114482A1 (zh) | 2020-06-11 |
EP3896062A1 (de) | 2021-10-20 |
AU2019392231B2 (en) | 2022-10-20 |
CA3122317C (en) | 2023-10-03 |
CN111285850A (zh) | 2020-06-16 |
CN111285850B (zh) | 2022-04-22 |
AU2019392231A1 (en) | 2021-07-29 |
CA3122317A1 (en) | 2020-06-11 |
US20220041578A1 (en) | 2022-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3896062A4 (de) | Isoindolinverbindung, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und verwendung der isoindolinverbindung | |
EP3862348A4 (de) | Isoindolinverbindung, herstellungsverfahren, pharmazeutische zusammensetzung und verwendung davon | |
EP3875458A4 (de) | Diphenylähnliche verbindungen, zwischenprodukte davon, herstellungsverfahren dafür, pharmazeutische zusammensetzung davon und verwendungen davon | |
EP3835296A4 (de) | Ketoamidverbindung und herstellungsverfahren, pharmazeutische zusammensetzung und verwendung davon | |
EP3753941A4 (de) | Pyrimidinkondensierte cyclische verbindung, verfahren zu ihrer herstellung und verwendung davon | |
EP3868399A4 (de) | Immunzusammensetzung, herstellungsverfahren dafür und anwendung davon | |
EP3539960A4 (de) | Stickstoffhaltige makrocyclische verbindung, herstellungsverfahren dafür, pharmazeutische zusammensetzung daraus und anwendung davon | |
EP3279207A4 (de) | Neuartige verbindung von 4'-thionukleosid sowie herstellungsverfahren dafür, pharmazeutische zusammensetzung davon und anwendung davon | |
EP3580208A4 (de) | Neuartige heterocyclische verbindung, deren herstellungsverfahren und pharmazeutische zusammensetzung damit | |
EP3626718A4 (de) | Fünf- und sechsgliedrige aza-aromatische verbindung, herstellungsverfahren dafür, pharmazeutische zusammensetzung und anwendung | |
EP3825322C0 (de) | Polypeptidverbindung, pharmazeutische zusammensetzung, verfahren zu ihrer herstellung und verwendung davon | |
EP3670511A4 (de) | Tetrahydroprotoberberinverbindung, verfahren zu ihrer herstellung und ihre verwendung sowie pharmazeutische zusammensetzung | |
EP4056571A4 (de) | Trizyklisches dihydroimidazopyrimidonderivat, verfahren zu seiner herstellung, pharmazeutische zusammensetzung und verwendung davon | |
EP3647313A4 (de) | Substituierte aryletherverbindung, herstellungsverfahren dafür, pharmazeutische zusammensetzung und verwendung davon | |
EP3750886A4 (de) | Tetrahydroisochinolinverbindung, herstellungsverfahren dafür, pharmazeutische zusammensetzung damit und verwendung davon | |
EP3744316A4 (de) | Ophthalmische pharmazeutische zusammensetzung, herstellungsverfahren dafür und anwendung davon | |
SG11202110674XA (en) | Compound, method and pharmaceutical composition for modulating expression of dux4 | |
EP3838265A4 (de) | Injizierbare pharmazeutische zusammensetzung und herstellungsverfahren dafür | |
EP3842426A4 (de) | Herstellungsverfahren von pyrrolo-amino-pyridazinon-verbindungen und zwischenprodukt davon | |
EP3760191A4 (de) | Pharmazeutische zusammensetzung, herstellungsverfahren dafür sowie verwendung davon | |
EP3808751A4 (de) | Camptothecinderivat, herstellungsverfahren dafür und anwendung davon | |
EP3785713A4 (de) | Salz von cetagliptin, herstellungsverfahren dafür, pharmazeutische zusammensetzung und verwendung davon | |
EP4056551A4 (de) | Kristallform i eines curcumin-derivats, herstellungsverfahren dafür und verwendung davon | |
EP3929198A4 (de) | Heterocyclische verbindung, pharmazeutische zusammensetzung damit, verfahren zu ihrer herstellung und ihre verwendung | |
EP3492461A4 (de) | Stickstoffhaltige heterocyclische aromatische verbindung, herstellungsverfahren dafür, pharmazeutische zusammensetzung daraus und anwendung davon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210705 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40053022 Country of ref document: HK |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220513 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20220509BHEP Ipc: A61K 31/4745 20060101ALI20220509BHEP Ipc: A61K 31/4412 20060101ALI20220509BHEP Ipc: C07D 401/14 20060101ALI20220509BHEP Ipc: C07D 401/04 20060101AFI20220509BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231106 |